U.S. Markets open in 4 mins

Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

Daniel Collins
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).